caus
outbreak
sever
acut
respiratori
syndrom
sar
individu
infect
death
worldwid
carri
protein
chip
array
profil
analysi
attempt
identifi
biomark
might
use
monitor
clinic
cours
sar
patient
method
perform
surfaceenhanc
laser
desorpt
ioniz
timeofflight
mass
spectrometri
sera
collect
sar
patient
sera
control
patient
variou
viral
bacteri
infect
sera
appar
healthi
individu
result
nine
significantli
increas
three
significantli
decreas
serum
biomark
discov
sar
patient
compar
control
among
biomark
one
da
identifi
serum
amyloid
saa
protein
peptid
map
tandem
mass
spectrometr
analysi
monitor
saa
concentr
longitudin
sera
four
sar
patient
found
good
correl
saa
concentr
extent
pneumonia
assess
serial
chest
xray
opac
score
increas
saa
occur
three
four
patient
time
extens
pneumonia
indic
high
xray
score
cours
gradual
recoveri
two
patient
assess
clinic
radiolog
saa
concentr
gradual
decreas
third
patient
concentr
initi
increas
increas
superimpos
multipl
bacteri
infect
saa
markedli
increas
fourth
patient
low
xray
score
whose
clinic
cours
rel
mild
conclus
protein
chip
array
profil
analysi
could
potenti
use
monitor
sever
diseas
sar
patient
new
strain
coronaviru
cov
caus
pandem
outbreak
sever
acut
respiratori
syndrom
sar
mainland
china
hong
kong
singapor
toronto
taiwan
infect
death
pneumonia
accompani
adult
respiratori
distress
syndrom
rapidli
progress
lead
death
commonli
use
laboratori
diagnost
test
sarscov
infect
revers
transcriptionpcr
rtpcr
respiratori
rectal
stool
sampl
antisarscov
antibodi
serolog
studi
appear
role
monitor
pneumonia
although
serial
chest
radiograph
help
monitor
progress
diseas
object
marker
well
describ
studi
analyz
serum
protein
sar
patient
power
proteom
technolog
surfaceenhanc
laser
desorptionion
timeofflight
mass
spectrometri
selditof
ms
short
protein
chip
array
profil
attempt
identifi
biomark
differenti
increas
decreas
sar
patient
subsequ
investig
possibl
role
biomark
diseas
monitor
serum
sampl
sar
patient
manag
depart
medicin
queen
elizabeth
hospit
hong
kong
studi
diagnos
patient
confirm
posit
rtpcr
test
sarscov
rna
antisarscov
antibodi
serolog
test
clinic
pictur
cohort
patient
similar
report
literatur
patient
abnorm
chest
radiograph
admiss
present
earli
highresolut
thorac
comput
tomographi
ct
scan
requir
confirm
presenc
pulmonari
involv
patient
initi
manag
broadspectrum
antibiot
support
therapi
diagnosi
clinic
sar
made
respons
antibiot
therapi
combin
therapi
ribavirin
mg
intraven
everi
h
system
steroid
intraven
hydrocortison
mg
everi
h
intraven
methylprednisolon
mg
kg
day
initi
latter
would
continu
tail
manner
total
day
intraven
puls
methylprednisolon
daili
dose
mg
g
day
would
initi
clinic
condit
radiolog
present
oxygen
satur
statu
deterior
least
two
three
clinic
characterist
detail
manag
plan
treatment
regimen
cohort
patient
describ
previou
public
fortyfour
serum
sampl
avail
sar
patient
initi
express
differenti
map
serum
protein
protein
chip
array
profil
identifi
biomark
differenti
increas
decreas
patient
addit
serial
sampl
avail
four
addit
sar
patient
comprehens
clinic
followup
seventytwo
sera
patient
suffer
infect
influenza
viru
sera
patient
influenza
b
viru
sera
patient
respiratori
adenoviru
sera
patient
respiratori
syncyti
viru
sera
patient
hepat
b
viru
sera
patient
mycobacterium
tuberculosi
sera
patient
variou
bacteria
posit
bacteri
cultur
sera
patient
plu
sera
appar
healthi
individu
attend
famili
nasopharyng
cancer
screen
clinic
shown
malign
serv
neg
control
studi
sera
collect
aliquot
variou
routin
laboratori
test
remain
sera
kept
frozen
protein
chip
array
profil
analysi
perform
sever
extent
pneumonia
four
sar
patient
longitudin
followup
assess
radiologist
blind
clinic
manifest
use
serial
chest
radiograph
score
deriv
initi
assess
comput
tomographi
chest
briefli
frontal
chest
xray
radiograph
divid
six
lung
zone
left
upper
zone
left
middl
zone
left
lower
zone
right
upper
zone
right
middl
zone
right
lower
zone
upper
zone
repres
area
carina
includ
apex
middl
zone
carina
level
inferior
pulmonari
vein
lower
zone
lower
margin
middl
zone
lung
base
opac
lung
zone
score
coars
semiquantit
method
fivepoint
scale
grade
repres
involv
area
respect
grade
six
lung
zone
ad
provid
point
summat
scale
protein
sar
control
sera
first
fraction
use
anionexchang
qhyper
ceram
resin
ciphergen
biosystem
silent
screen
filter
plate
pore
size
briefli
resin
prepar
wash
five
bed
volum
mmoll
trishcl
ph
three
time
equilibr
filter
plate
lwell
mmoll
trishcl
buffer
contain
moll
urea
gl
chap
moll
urea
buffer
sera
remov
freezer
thaw
l
serum
denatur
ad
l
mmoll
trishcl
buffer
contain
moll
urea
gl
chap
vortexmix
min
sampl
mixtur
load
well
filter
plate
l
moll
urea
buffer
ad
plate
shaken
orbit
shaker
min
centrifug
collect
plate
place
underneath
min
collect
flowthrough
fraction
ad
l
mmoll
trishcl
buffer
contain
gl
ogp
ph
ph
wash
buffer
plate
rins
resin
vigor
vortexmix
orbit
shaker
min
rins
collect
centrifug
mix
togeth
previous
flowthrough
fraction
fraction
repeat
similarli
ph
wash
buffer
mmoll
sodium
phosphat
contain
gl
ogp
ph
ph
wash
buffer
mmoll
sodium
acet
contain
gl
ogp
ph
ph
wash
buffer
mmoll
sodium
acet
contain
gl
ogp
ph
ph
wash
buffer
mmoll
sodium
citrat
contain
gl
ogp
ph
final
organ
wash
buffer
mll
isopropanol
mll
acetonitril
mll
trifluoroacet
acid
six
result
serum
anionexchang
fraction
repres
flowthrough
fraction
ph
fraction
ph
ph
ph
ph
organ
fraction
respect
frozen
chip
bind
initi
six
serum
fraction
profil
copper
ii
immobil
metal
affin
captur
imac
cu
ii
proteinchip
array
weak
cationexchang
proteinchip
array
accord
instruct
manual
ciphergen
biosystem
incorpor
pretreat
step
requir
imac
cu
ii
chip
chip
briefli
imac
cu
ii
chip
load
bioprocessor
spot
chip
ad
l
mmoll
cuso
buffer
chip
vortexmix
vigor
rins
distil
water
l
mmoll
sodium
acet
buffer
ad
chip
strong
vortexmix
remov
unbound
copper
chip
rins
water
equilibr
chip
bind
buffer
mmoll
sodium
phosphat
buffer
ph
contain
moll
nacl
ad
l
chip
bind
buffer
spot
imac
cu
ii
chip
respect
ad
l
serum
fraction
imac
cu
ii
chip
respect
follow
vigor
vortexmix
min
room
temperatur
chip
wash
twice
l
chip
bind
buffer
vortexmix
min
wash
twice
l
distil
water
one
microlit
energyabsorb
molecul
sinapin
acid
mll
mll
trifluoroacet
acid
appli
twice
spot
chip
airdri
min
applic
chip
read
protein
biolog
system
iic
mass
spectromet
reader
ciphergen
biosystem
incorpor
timeofflight
spectra
gener
averag
laser
shot
per
sampl
mass
accuraci
calibr
extern
use
peptid
molecular
mass
standard
ciphergen
biosystem
incorpor
control
run
concurr
intermingl
patient
sampl
chip
multipl
chip
variabl
analys
also
perform
analyz
spottospot
chiptochip
variat
imac
cu
ii
chip
briefli
refer
serum
sampl
repeatedli
bound
four
differ
spot
four
differ
chip
use
ionexchang
serum
fraction
imac
cu
ii
chip
fraction
chip
pool
cv
peak
signaltonois
ratio
mass
rang
kda
calcul
protein
chip
profil
spectra
serum
sampl
collect
analyz
ciphergen
proteinchip
softwar
mass
rang
kda
analyz
molecul
da
elimin
artifact
produc
energyabsorb
molecul
chemic
contamin
usual
lie
mass
rang
peak
baselinesubtract
calibr
mass
accuraci
detect
cluster
automat
analysi
softwar
biomark
wizard
mode
normal
peak
height
intens
peak
detect
sera
sar
patient
compar
control
group
nonparametr
twosampl
mannwhitney
utest
identifi
peak
significantli
increas
decreas
sar
patient
briefli
done
oper
two
pass
first
pass
detect
major
welldefin
peak
differ
sar
control
group
second
pass
defin
remain
small
peak
differ
group
use
criterion
twofold
greater
differ
peak
height
data
normal
two
group
normal
peak
intens
sar
patient
longitudin
followup
also
correl
chest
xray
opac
score
clinic
manifest
protein
identif
subject
fraction
ionexchang
filtrat
sar
sera
purif
use
immobil
copper
ion
spin
column
idacu
hypercel
ciphergen
biosystem
bound
protein
elut
boil
sampl
load
buffer
sodium
dodecyl
sulfatepolyacrylamid
gel
electrophoresi
sdspage
elut
antigen
resolv
sdspage
gradient
gel
nupag
invitrogen
protein
band
kda
gel
excis
protein
band
subject
overnight
tryptic
digest
reaction
volum
l
mmoll
ammonium
bicarbon
buffer
ph
contain
pmole
trypsin
subsequ
l
digest
mixtur
analyz
normal
phase
proteinchip
array
acid
ciphergen
biosystem
use
facilit
desorptionion
peptid
gener
tryptic
digest
mass
tryptic
digest
peptid
measur
proteinchip
reader
use
initi
protein
identif
profound
databas
avail
internet
clinic
chemistri
http
prowlrockefelleredu
ident
protein
confirm
tandem
mass
spectrometri
msm
fragment
analysi
five
major
peptid
molecular
mass
da
gener
tryptic
digest
abi
qstar
tm
quadrupol
tandem
mass
spectromet
equip
ciphergen
proteinchip
interfac
describ
previous
fragment
peptid
gener
set
msm
ion
fingerprint
enter
mass
spectrometri
databas
search
engin
mascot
http
wwwmatrixsci
com
find
closest
match
known
protein
report
previous
probabilitybas
mows
score
thu
gener
indic
msm
ion
profil
match
good
homolog
known
protein
databas
p
valu
wherea
score
repres
match
known
protein
almost
absolut
ident
biomark
resolv
protein
chip
array
profil
six
fraction
anionexchang
filtrat
sar
patient
serum
fig
show
gel
view
part
profil
result
sar
patient
conjunct
control
patient
molecular
size
rang
da
three
serum
biomark
cluster
b
c
fig
differenti
express
sar
patient
vs
control
observ
cluster
da
cluster
increas
sar
patient
remain
two
cluster
da
cluster
b
c
decreas
analyz
whole
serum
biomark
profil
identifi
nine
biomark
molecular
size
da
respect
significantli
increas
three
molecular
size
da
significantli
decreas
sar
patient
vs
control
infect
group
appar
healthi
individu
tabl
analysi
distribut
rel
peak
intens
biomark
da
show
signific
increas
sar
patient
individu
control
infect
group
healthi
individu
fig
investig
whether
protein
chip
profil
result
consist
reproduc
test
ionexchang
fraction
refer
serum
four
differ
spot
chip
spottospot
variabl
spot
four
differ
chip
chiptochip
variabl
see
tabl
data
supplement
accompani
onlin
version
articl
http
cv
mean
intens
variou
peak
imac
cu
ii
chip
chip
determin
chiptochip
cv
imac
cu
ii
chip
vari
small
larg
mass
rang
wherea
spottospot
cv
vari
chip
rel
higher
variabl
chiptochip
cv
spottospot
cv
howev
variabl
within
reason
rang
us
compar
peak
intens
sar
control
group
correl
peak
intens
biomark
da
clinic
manifest
radiograph
score
sar
patient
character
natur
biomark
da
subject
protein
band
kda
resolv
sdspage
tryptic
digest
gener
seri
peptid
fragment
fig
submit
peptid
fragment
profound
databas
search
engin
match
probabl
human
serum
amyloid
protein
saa
first
choic
saa
match
probabl
second
choic
human
hypothet
protein
probabl
confirm
ident
saa
perform
separ
fragment
analys
tandem
mass
spectromet
five
peptid
gener
tryptic
digest
protein
fig
one
msm
ion
fingerprint
gener
peptid
da
fig
enter
ion
fingerprint
peptid
mass
spectrometri
search
engin
databas
mascot
gave
mows
score
indic
almost
absolut
ident
human
saa
confirm
tryptic
map
find
ion
fingerprint
remain
four
peptid
also
confirm
saa
predomin
protein
data
shown
saa
identifi
one
predominantli
increas
biomark
sar
patient
correl
concentr
clinic
find
serial
chest
radiograph
score
four
sar
patient
follow
cov
infect
diagnos
radiograph
score
first
patient
longitudin
followup
start
increas
valu
peak
gradual
decreas
final
demonstr
progress
recoveri
fig
onlin
data
supplement
saa
concentr
protein
chip
profil
show
increas
peak
earlier
radiograph
score
also
gradual
decreas
along
radiograph
score
nadir
patient
discharg
second
patient
clinic
sar
symptom
sarscov
infect
subsequ
confirm
rtpcr
treatment
radiograph
score
remain
high
initi
decreas
progress
recoveri
fig
onlin
data
supplement
protein
chip
profil
also
reveal
saa
concentr
increas
initi
soon
decreas
similarli
radiograph
score
saa
peak
also
preced
score
third
patient
typic
clinic
sar
symptom
viral
diseas
confirm
pair
serum
antisarscov
antibodi
test
perform
twice
clinic
cours
treatment
unev
low
radiograph
score
later
decreas
zero
saa
concentr
low
throughout
monitor
period
fig
onlin
data
supplement
despit
treatment
pneumon
condit
fourth
patient
remain
sever
high
radiograph
score
day
treatment
saa
concentr
began
increas
well
increas
diagnosi
superimpos
bacteri
infect
fig
onlin
data
supplement
subsequ
decreas
saa
concentr
observ
initi
antibiot
treatment
although
remain
significantli
increas
thereaft
patient
still
harbor
viru
indic
posit
rtpcr
variou
sourc
radiograph
score
remain
high
later
die
diseas
convent
cov
usual
caus
mild
selflimit
coldlik
symptom
rare
sever
lower
respiratori
tract
infect
contrast
sarscov
give
rise
rapidli
progress
pneumonia
associ
significantli
high
mortal
rate
sar
patient
develop
pulmonari
infiltr
within
h
onset
diseas
usual
form
focal
unilater
consolid
peripher
region
lung
consolid
usual
clear
quickli
small
proport
patient
progress
bilater
consolid
extens
pneumon
involv
protract
clinic
cours
serial
chest
radiograph
help
diagnosi
monitor
clinic
cours
interpret
confound
lack
avail
experienc
radiologist
interobserv
variabl
frequent
suboptim
qualiti
portabl
film
taken
isol
ward
avoid
spread
infect
patient
sarscov
antibodi
usual
increas
later
stage
diseas
therefor
good
marker
monitor
extent
diseas
high
titer
predict
need
intens
care
suggest
quantit
realtim
rtpcr
determin
viral
load
may
prognost
valu
howev
use
monitor
diseas
probabl
limit
least
unclear
lung
damag
sar
appear
relat
immunopatholog
consequ
host
respons
viru
replic
also
suggest
lymphopenia
tcell
lymphopenia
fairli
common
occurr
sar
patient
might
potenti
marker
diseas
activ
howev
presenc
superimpos
viral
bacteri
infect
well
effect
treatment
steroid
intraven
immunoglobulin
might
also
affect
lymphocyt
count
make
less
ideal
monitor
diseas
activ
sar
high
serum
lactat
dehydrogenas
concentr
report
associ
advers
patient
outcom
concentr
peak
height
diseas
decreas
within
refer
valu
remiss
discharg
enzym
origin
mani
sourc
heart
skelet
muscl
erythrocyt
liver
increas
might
also
attribut
diseas
condit
organ
diseas
complic
rhabdomyolysi
hemolyt
anemia
ribavirin
treatment
henc
chang
lactat
dehydrogenas
activ
might
specif
enough
monitor
diseas
modern
mass
spectrometri
revolution
proteom
studi
enabl
rapid
resolut
biomark
singl
serum
sampl
larg
number
sampl
also
process
within
short
period
time
selditof
ms
protein
chip
profil
advanc
technolog
combin
mass
spectrometri
surfaceenhanc
biochip
allow
uniform
reproduc
bind
desorpt
biomark
quantit
comparison
individu
resolv
biomark
serial
monitor
patient
possibl
use
profil
technolog
found
least
serum
biomark
differenti
increas
decreas
sar
patient
among
acutephas
protein
saa
substanti
increas
sera
sar
patient
contrast
sera
control
patient
differ
viral
bacteri
infec
tion
use
clinic
use
chest
radiograph
score
found
saa
concentr
correl
well
extent
pneumonia
four
patient
serial
serum
sampl
avail
first
two
patient
protein
increas
similar
increas
radiograph
score
activ
phase
diseas
within
first
week
symptom
onset
slightli
earlier
peak
saa
concentr
compar
radiograph
score
could
perhap
indic
saa
might
earlier
marker
diseas
activ
although
requir
valid
third
patient
milder
diseas
cours
lesser
extent
pneumon
involv
saa
concentr
remain
rel
low
throughout
indic
biomark
correl
well
sever
diseas
acutephas
protein
synthes
liver
saa
report
increas
infecti
arthrit
diseas
malign
increas
found
promin
bacteri
infect
nonsarscov
viral
infect
henc
surpris
fourth
patient
demonstr
increas
saa
concentr
neartermin
part
ill
superimpos
bacteri
infect
follow
slight
decreas
antibiot
initi
increas
probabl
addit
persist
sarscov
infect
demonstr
persist
posit
rtpcr
result
sampl
variou
sourc
continu
sever
radiolog
abnorm
increas
saa
howev
contrast
low
concentr
protein
test
control
viral
bacteri
infect
fig
probabl
result
sever
multipl
superimpos
infect
septicemia
patient
secondari
sever
bacteri
infect
caus
high
mortal
uncommon
sar
patient
pneumonia
therefor
increas
saa
concentr
presenc
sever
secondari
infect
sar
patient
could
advantag
rather
disadvantag
aim
monitor
patient
sever
diseas
apart
saa
candid
acutephas
protein
acid
glycoprotein
antitrypsin
haptoglobulin
creactiv
protein
exist
variou
mammal
saa
found
sensit
creactiv
protein
detect
minor
inflammatori
stimuli
certain
viral
infect
noninvas
earli
invas
bacteri
infect
studi
felin
diseas
condit
also
show
saa
earliest
marker
induc
compar
acid
glycoprotein
haptoglobulin
creactiv
protein
lend
support
possibl
saa
might
also
manifest
earlier
radiograph
score
although
remain
confirm
subsequ
studi
despit
variou
report
potenti
applic
selditof
ms
diagnosi
variou
diseas
technolog
also
suggest
detect
highabund
protein
acutephas
reactant
far
sarscov
infect
concern
major
mortalitycaus
symptom
pneumonia
therefor
discoveri
acutephas
protein
strongli
associ
pneumoniarel
inflammatori
event
expect
entir
match
theme
studi
pneumonia
monitor
although
individu
acutephas
protein
detect
studi
may
absolut
specif
sarscov
infect
per
se
preliminari
data
show
seldi
analysi
show
distinct
pattern
increas
decreas
protein
variant
distinguish
sar
infecti
respiratori
diseas
well
data
shown
precis
mechan
increas
saa
concentr
sar
patient
remain
investig
pulmonari
infiltr
acutephas
diffus
alveolar
damag
frequent
found
sar
patient
also
wide
known
infiltr
diffus
alveolar
damag
serv
stimuli
product
secret
varieti
inflammatori
cytokin
sar
patient
shown
markedli
increas
plasma
concentr
two
inflammatori
cytokin
know
rapidli
induc
increas
saa
synergist
manner
thu
perhap
explain
possibl
rapid
induct
acutephas
reactant
time
sar
cov
infect
encourag
correl
saa
concentr
extent
pneumonia
possibl
correl
increas
decreas
remain
serum
biomark
diseas
condit
well
saa
probabl
biomark
discuss
could
use
monitor
diseas
activ
respons
treatment
sar
patient
